ASH 2023

Important data on transplant-eligible NDMM

Update on transplant-ineligible NDMM

Practice changing - Daratumumab before und after transplantation

Quatruplet therapy - the new standard in induction & consolidation in NDMM

CD38 antibodies - good in 1st line but bad in 2nd line?

Isa-KRd - practice changing?

Vierfachkombinationen - der neue Standard bei Induktion und Erhaltung

Daratumumab vor und nach Transplantation neuer Standard

CD38-antistoffer - bra i førstelinje men ikke i andrelinje?

Isa-KRd - practice changing?

The future of CAR T Cell treatment - I

The future of CAR T Cell treatment - II

Bispecific antibodies - update and outlook on treatment strategies

Survival data from KarMMa-3

cilta-cel in early lines

New data on efficacy and safety of CAR T cells and bispecifics/TCEs

Single-cell analysis of CAR T cells

Response predictors in immunotherapy

Early data on TriTac

Einzelzell-Analysen bei CAR-T-Zellen

Overlevelsesdata fra KarMMa-3

CAR-T-Zellen und bispezifische Antikörper/TCEs: Neue Daten zu Wirksamkeit und Sicherheit

cilta-cel in frühen Linien

Are we preventing myeloma yet?

First whole genome sequencing trial with long-term FUP in SMM treated with KRd/R maintenance

CENTAURUS: using single-drug Daratumumab in smoldering myeloma

Are we ready for screening?

First whole genome sequencing trial with long-term FUP in SMM treated with KRd/R maintenance

CENTAURUS: using single-drug Daratumumab in smoldering myeloma

Updates for immunotherapy of follicular lymphoma

Cost-effectiveness analysis of Mosunetuzumab and CAR T in R/R follicular lymphoma

Chemo-free combination for 1st line follicular lymphoma

Bispecific antibodies in follicular lymphoma (1st line)

Long-term follow-up of ELARA study

Real-world data of CAR T in relapsed follicular lymphoma

CAR T cells in follicular lymphoma (1st relapse)

Una combinazione chemo-free per la prima linea del linfoma follicolare

CAR-T-Zellen im follikulären Lymphom (erstes Rezidiv)

Analisi costo-beneficio di mosunetuzumab vs CART nel linfoma follicolare recidivato refrattario

Bispezifische Antikörper im follikulären Lymphom (1st line)

Follow-up a lungo termine dello studio ELARA

Data "real world" delle CART nel linfoma follicolare recidivato refrattario

No efficacy of vitamin D in rituximab therapy

Keine Wirksamkeit von Vitamin D bei Rituximab-Therapie

New data for MCL - part I

New data for MCL - part II

Adding Ara-C and lenalidomide to the standard RCHOP+RM did not improve survival in older patients

A new standard for R/R MCL?

Is obinutuzumab superior to rituximab in MCL?

Venetoclax added to RBAC significantly improves PFS in older patients with high-risk MCL

BOVEN: An effective MRD-guided strategy free of chemo for untreated TP53-mutated MCL

Sobering results for bendamustine and venotoclax in MCL (1st line)

The SYMPATICO study confirms the synergy between ibrutinib and venetoclax in rel/ref MCL

Ibrutinib plus Venetoclax in R/R MCL - a new treatment option!

TP53-mutant MCL - a new standard in 1st line?

Sequential use of R-bendamustine and ibrutinib?

Venetoclax mejora significativamente la PFS de RBAC en mayores con LCM de alto riesgo

Ny standardbehandling för recidiv av MCL?

MCL mit TP53-Mutation: Neuer Standard in der Erstlinie?

Vilken CD20-antikropp är att föredra vid MCL?

Ernüchternde Ergebnisse für Bendamustin und Venotoclax beim MCL 1st line

Añadir Ara-C y lenalidomida al estándar RCHOP+MR no mejora la supervivencia en pacientes mayores

Sekventiell eller samtidig behandling med R-bendamustin och ibrutinib?

El estudio SYMPATICO confirma la sinergia entre ibrutinib y venetoclax en el LCM rec/ref

Ibrutinib plus Venetoclax beim rezidivierenden MCL - eine neue Therapieoption!

BOVEN: Una estrategia sin quimio guiada por EMR, altamente eficaz en el LCM con mutaciones de TP53

Highlights in chronic lymphocytic leukemia

Sonrotoclax plus zanubrutinib in 1st line CLL

Pirtobrutinib in relapsed CLL

Ibrutinib plus venetoclax as MRD-guided treatment

Bv-AVD in older patients

Nivo-AVD bei älteren Patienten besser als Bv-AVD

DLBCL - new treatment approaches and diagnostic procedures